LATEST ALERTS
Public health insurance reimbursements and no defined list of indications for medical cannabis have helped the German medical cannabis market start to realise its massive potential
Research from a CBD watchdog firm has found considerable inconsistencies between the levels of delta-8 THC stated on product labels and what was revealed by laboratory tests
Both synthetic and plant-derived CBD degrade when stored incorrectly, producing THC, according to a new study
London-listed Kanabo has launched the first medical cannabis vaping product in the UK in a move the company’s founder hopes will ultimately revolutionise the way medicines are administered
Medical cannabis advocates are keen to see if Sajid Javid’s appointment as UK health secretary means he will continue his work from 2018, when he helped change the law on medicinal cannabis prescriptions
A range of European firms are looking to further advance research into psychedelic compounds after securing funding and backing
A year and eight months after Cibdol submitted its novel food application for EU authorisation of synthetically produced CBD, the Swiss company is still fielding questions from the European Food Safety Authority (ESFA)
What are the potential implications for the cannabinoids market of two recently discovered compounds with chemical structures similar to those of CBD and THC – and what are they and their potential effects anyway?
France is lagging behind its neighbours on medical cannabis – the potential “green pig” of French agriculture – according to an author of a report which called for it to be legalised on health and finance grounds
CBD-Intel podcast editor Jon Bruford discusses the situation of medical cannabis and the challenges of hemp-growing in the UK with Dr Callie Seaman, research director at Aqualabs Ltd
Trends such as sustainability and organic plant-based ingredients are helping to drive the market for hemp and cannabinoid topical products even higher, with combination products all the rage
CBD-Intel assesses how Project Twenty21 is faring as it seeks to construct a registry of medical cannabis users in the UK and Europe, providing real world data on potential efficacy
Pain is a familiar part of everybody’s life, yet it remains a remarkably hard subject to study. It therefore is unsurprising that studies have come to differing conclusions on the use of cannabis and cannabinoids for pain relief
CBD-Intel offers a review of the science behind some of cannabis’s lesser-known compounds – the so-called “minor cannabinoids” – with an emphasis on their potential applications
In comparison with our 2019 consumer survey results, the reasons given for using CBD have changed and diversified
Early research into the possibility of CBD having a role to play in the fight against coronavirus infections has shown some initial promise. Any practical application remains a long way off, however
Australian medicinal cannabis firm Cann has moved quickly to maximise the benefits of its CBD Gelpell capsule technology by entering into a collaboration deal with healthcare technology firm Emyria
While legal cannabis is still a relatively new industry, investors are already looking for the next sector to boom – and many think that will be psychedelics
Canadian cannabis firm Tilray is moving in on New Zealand’s market for medical cannabis and has received the necessary approvals to launch Tilray medical cannabis products across the country
Could cannabinoids, including CBD, provide a partial solution to the growing danger of diseases becoming resistant to existing antibiotics?
Scientific findings on the antimicrobial properties of cannabis – and in particular cannabinoids – have raised the question of whether they might play a role in combatting antibiotic-resistant bacteria such as MRSA
The CEO of one company targeted by the US Federal Trade Commission (FTC) in the first ever group of fines handed down by the government agency to CBD companies considers the event to be a David and Goliath victory of sorts
No evidence of liver toxicity from CBD has been found in the ValidCare study, the results of which have been given to the US Food and Drug Administration (FDA) for review
Any conclusion drawn from studies on rodents must be treated with caution if we want to know about effects on humans
The US Food and Drug Administration (FDA) has called for an exploration of the effects of CBD on certain vulnerable populations such as children and pregnant women as part of its consumer update
GW Pharmaceuticals, the British manufacturer of the CBD-based epilepsy drug Epidiolex, has been acquired by Jazz Pharmaceuticals in a cash and shares deal worth over $7bn
Renewed interest in financing of CBD and cannabis businesses could signal that investors are starting to be positive again about the future after companies seemingly weathered the worst of the storm in 2020
Dutch officials have granted a six-month reprieve to find a solution to an omission in the Brexit negotiations that threatens to deprive British epilepsy patients of access to cannabis-based medicines
Find all of CBD-Intel’s coronavirus-related regulatory alerts here, updated as they appear
For many 2020 will always carry an asterisk. The CBD industry was – overall – more fortunate than many other sectors
Efforts to supply the first CBD product to Brazil’s public healthcare system will have to wait a while longer – and there is some dispute between the institute preparing to produce it and the sponsors of a Congress bill
Increasing numbers of celebrities are endorsing CBD products, with names as big as will.i.am, Jay-Z, Beyoncé and Gwyneth Paltrow among those investing or launching their own brands
Another company has been warned by the US Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) to stop claiming CBD can cure or mitigate the symptoms of COVID-19
The Court of Justice of the European Union’s (CJEU) decision in the Kanavape case will have a tremendous impact on the CBD industry in the European Union (EU). However, the breadth of its impact is not yet fully realised. A number of things must happen beforehand and it may come down to further court rulings before a baseline level of requirements and » Continue Reading.
Pharmaceutical firms continue to invest in research into the healing potential of cannabinoids, launching clinical trials to investigate their ability to treat a range of conditions
While solid research explaining the science behind CBD remains lacking as the market continues to grow, some bad actors in the industry are making false scientific claims for their products
The announcement is a full reversal from the EC on a position that many found surprising in the first place. It marks a stellar period for the regulation of CBD and other cannabinoids with major decisions in their favour at the Court of Justice of the European Union, United Nations and now the EC. The resumption of novel food assessment » Continue Reading.
The results of Canada’s public consultation on health products containing cannabis have been released, showing strong support for allowing the sale of CBD outside the current cannabis restrictions
The Isle of Man looks likely to become the second jurisdiction operating under UK regulations to allow the use of hemp flowers in extraction
Overall it seems the industry – particularly in Europe – is not expecting much from Black Friday sales. European companies appear to consider CBD products more as health products that are requirement purchases throughout the year as opposed to lifestyle products that might be purchased as a one off during a special sales event. The situation may be slightly different in the US where Black Friday – » Continue Reading.
How important is the CJEU decision on the Kanavape case? The judgement in favour of CBD from the Courts of Justice of the European Union (CJEU) will almost certainly have significant long-term consequences for the CBD industry in Europe. It will likely influence the European Commission (EC)’s further assessment of the question of whether CBD is a narcotic. The preliminary opinion » Continue Reading.
CBD, generally seen as a health or wellness product, and “bad guy” nicotine are almost opposites in terms of public perception – but could putting the two together make commercial sense?
Mexico is overall the number one country to watch, rated highly likely to change regulations on both medical and recreational cannabis in the near future.
The US Food and Drink Administration (FDA) has issued a warning letter to the CBD company For Our Vets over COVID-19 health claims
There are still quite a few unanswered questions regarding the novel food application process under the FSA. Fortunately the requirement of having toxicological data
Commercial interest in mushrooms as active ingredients is on the rise – despite legal issues that severely curtail commercial opportunities
Increasing numbers of CBD businesses are marketing products that chime with the wellness trend and now even Playboy is launching a line of CBD products in the US that promise physical and mental benefits
Maria Alejandra Estanga, our market analysts, presented the current status of the topicals market across the most important CBD markets during the Virtual Cannacosmo Health + Beauty Expo on 29st September.
A proposal to be voted on by Brazilian legislators in the coming weeks could legalise the growing of hemp for industrial purposes and cannabis for medical use
The Association for the Cannabinoid Industry (ACI) will move forward with its consortium approach to obtaining toxicology and safety data for CBD with at least 15 companies having signed up and an undisclosed number still in discussion
Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.
"*" indicates required fields
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
